Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer

References

1. 1.↵
   2. Bray F,
   3. Ferlay J,
   4. Soerjomataram I,
   5. Siegel RL,
   6. Torre LA,
   7. Jemal A.

   Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;
2. 2.↵
   2. Bast RC,
   3. Hennessy B,
   4. Mills GB.

   The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009; 9: 415.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   2. Hollis RL,
   3. Gourley C.

   Genetic and molecular changes in ovarian cancer. Cancer Biol Med. 2016; 13: 236–47.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   2. Prat J.

   Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014; 124: 1–5.

   OpenUrlCrossRefPubMed
5. 5.↵
   2. Prat J.

   Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012; 460: 237–49.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.
   2. Markman M,
   3. Bookman MA.

   Second-line treatment of ovarian cancer. Oncologist. 2000; 5: 26–35.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   2. Cooke SL,
   3. Brenton JD.

   Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol. 2011; 12: 1169–74.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   2. Hynes NE,
   3. MacDonald G.

   ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 2009; 21: 177–84.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   2. Brustmann H.

   Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome. Int J Gynecol Pathol. 2008; 27: 380–9.

   OpenUrlCrossRefPubMed
10. 10.↵
    2. Verri E,
    3. Guglielmini P,
    4. Puntoni M,
    5. Perdelli L,
    6. Papadia A,
    7. Lorenzi P, et al.

    HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. Oncology. 2005; 68: 154–61.

    OpenUrl
11. 11.↵
    2. Tanner B,
    3. Hasenclever D,
    4. Stern K,
    5. Schormann W,
    6. Bezler M,
    7. Hermes M, et al.

    ErbB-3 predicts survival in ovarian cancer. J Clin Oncol. 2006; 24: 4317–23.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    2. Lassus H,
    3. Sihto H,
    4. Leminen A,
    5. Joensuu H,
    6. Isola J,
    7. Nupponen NN, et al.

    Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med. 2006; 84: 671–81.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    2. Marmor MD,
    3. Skaria KB,
    4. Yarden Y.

    Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys. 2004; 58: 903–13.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    2. Casalini P,
    3. Iorio MV,
    4. Galmozzi E,
    5. Ménard S.

    Role of HER receptors family in development and differentiation. J Cell Physiol. 2004; 200: 343–50.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    2. Roskoski R Jr..

    The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun. 2004; 319: 1–11.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    2. Wee P,
    3. Wang Z.

    Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers. 2017; 9: 52.

    OpenUrl
17. 17.↵
    2. Teplinsky E,
    3. Muggia F.

    EGFR and HER2: is there a role in ovarian cancer? Transl Cancer Res. 2015; 4: 107–17.

    OpenUrl
18. 18.↵
    2. Dhillon AS,
    3. Hagan S,
    4. Rath O,
    5. Kolch W.

    MAP kinase signalling pathways in cancer. Oncogene. 2007; 26: 3279–90.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    2. Cloven NG,
    3. Kyshtoobayeva A,
    4. Burger RA,
    5. Yu I-R,
    6. Fruehauf JP.

    In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. Gynecol Oncol. 2004; 92: 160–66.

    OpenUrlCrossRefPubMedWeb of Science
20. 20.
    2. Nielsen JS,
    3. Jakobsen E,
    4. HØlund B,
    5. Bertelsen K,
    6. Jakobsen A.

    Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer. 2004; 14: 1086–96.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    2. Bartlett JM,
    3. Langdon SP,
    4. Simpson BJ,
    5. Stewart M,
    6. Katsaros D,
    7. Sismondi P, et al.

    The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer. 1996; 73: 301–06.

    OpenUrlCrossRefPubMedWeb of Science
22. 22.↵
    2. Wang K,
    3. Li D,
    4. Sun L.

    High levels of EGFR expression in tumor stroma are associated with aggressive clinical features in epithelial ovarian cancer. Onco Targets Ther. 2016; 9: 377–86.

    OpenUrl
23. 23.↵
    2. Farley J,
    3. Fuchiuji S,
    4. Darcy KM,
    5. Tian C,
    6. Hoskins WJ,
    7. McGuire WP, et al.

    Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study. Gynecol Oncol. 2009; 113: 341–7.

    OpenUrlCrossRefPubMed
24. 24.↵
    2. Slamon DJ,
    3. Godolphin W,
    4. Jones LA,
    5. Holt JA,
    6. Wong SG,
    7. Keith DE, et al.

    Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244: 707–12.

    OpenUrlAbstract/FREE Full Text
25. 25.↵
    2. Anglesio MS,
    3. Kommoss S,
    4. Tolcher MC,
    5. Clarke B,
    6. Galletta L,
    7. Porter H, et al.

    Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol. 2013; 229: 111–20.

    OpenUrlCrossRefPubMedWeb of Science
26. 26.↵
    2. Tan DS,
    3. Iravani M,
    4. McCluggage WG,
    5. Lambros MB,
    6. Milanezi F,
    7. Mackay A, et al.

    Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin Cancer Res. 2011; 17: 1521–34.

    OpenUrlAbstract/FREE Full Text
27. 27.↵
    2. McCaughan H,
    3. Um I,
    4. Langdon SP,
    5. Harrison DJ,
    6. Faratian D.

    HER2 expression in ovarian carcinoma: caution and complexity in biomarker analysis. J Clin Pathol. Published online first: March 12, 2012. DOI: 10.1136/jclinpath-2011-200616.

    OpenUrlFREE Full Text
28. 28.↵
    2. Shang A-Q,
    3. Wu J,
    4. Bi F,
    5. Zhang Y-J,
    6. Xu L-R,
    7. Li L-L, et al.

    Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer. Cancer Biol Ther. 2017; 18: 314–22.

    OpenUrlCrossRefPubMed
29. 29.↵
    2. Lee H,
    3. Maihle NJ.

    Isolation and characterization of four alternate c-erbB3 transcripts expressed in ovarian carcinoma-derived cell lines and normal human tissues. Oncogene. 1998; 16: 3243–52.

    OpenUrlCrossRefPubMedWeb of Science
30. 30.↵
    2. Srinivasan R,
    3. Leverton KE,
    4. Sheldon H,
    5. Hurst HC,
    6. Sarraf C,
    7. Gullick WJ.

    Intracellular expression of the truncated extracellular domain of c-erbB-3/HER3. Cell Signal. 2001; 13: 321–30.

    OpenUrlCrossRefPubMedWeb of Science
31. 31.↵
    2. Davies S,
    3. Holmes A,
    4. Lomo L,
    5. Steinkamp MP,
    6. Kang H,
    7. Muller CY, et al.

    High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer. Int J Gynecol Pathol. 2014; 33: 402–10.

    OpenUrlCrossRefPubMed
32. 32.↵
    2. Simpson BJ,
    3. Weatherill J,
    4. Miller EP,
    5. Lessells AM,
    6. Langdon SP,
    7. Miller WR.

    c-erbB-3 protein expression in ovarian tumours. Br J Cancer. 1995; 71: 758–62.

    OpenUrlPubMedWeb of Science
33. 33.↵
    2. Roskoski R.

    The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014; 79: 34–74.

    OpenUrlCrossRefPubMed
34. 34.↵
    2. Engelman JA,
    3. Zejnullahu K,
    4. Mitsudomi T,
    5. Song Y,
    6. Hyland C,
    7. Park JO, et al.

    MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007; 316: 1039–43.

    OpenUrlAbstract/FREE Full Text
35. 35.
    2. Krumbach R,
    3. Schuler J,
    4. Hofmann M,
    5. Giesemann T,
    6. Fiebig HH,
    7. Beckers T.

    Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur J Cancer. 2011; 47: 1231–43.

    OpenUrlCrossRefPubMedWeb of Science
36. 36.↵
    2. Grovdal LM,
    3. Kim J,
    4. Holst MR,
    5. Knudsen SL,
    6. Grandal MV,
    7. van Deurs B.

    EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells. Cell Signal. 2012; 24: 296–301.

    OpenUrlCrossRefPubMed
37. 37.↵
    2. Bezler M,
    3. Hengstler JG,
    4. Ullrich A.

    Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells. Mol Oncol. 2012; 6: 516–29.

    OpenUrlCrossRefPubMed
38. 38.↵
    2. Chandarlapaty S,
    3. Sawai A,
    4. Scaltriti M,
    5. Rodrik-Outmezguine V,
    6. Grbovic-Huezo O,
    7. Serra V, et al.

    AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity. Cancer Cell. 2011; 19: 58–71.

    OpenUrlCrossRefPubMedWeb of Science
39. 39.↵
    2. Sheng Q,
    3. Liu J.

    The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br J Cancer. 2011; 104: 1241–45.

    OpenUrlCrossRefPubMedWeb of Science
40. 40.↵
    2. Jones FE.

    HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer. J Mammary Gland Biol Neoplasia. 2008; 13: 247–58.

    OpenUrlCrossRefPubMedWeb of Science
41. 41.↵
    2. Scoccia B,
    3. Lee YM,
    4. Niederberger C,
    5. Ilekis JV.

    Expression of the ErbB family of receptors in ovarian cancer. J Soc Gynecol Investig. 1998; 5: 161–65.

    OpenUrlCrossRefPubMed
42. 42.↵
    2. Saglam O,
    3. Xiong Y,
    4. Marchion DC,
    5. Strosberg C,
    6. Wenham RM,
    7. Johnson JJ, et al.

    ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy. Cancer Control. 2017; 24: 89–95.

    OpenUrl
43. 43.↵
    2. Steffensen KD,
    3. Waldstrom M,
    4. Andersen RF,
    5. Olsen DA,
    6. Jeppesen U,
    7. Knudsen HJ, et al.

    Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors. Int J Oncol. 2008; 33: 195–204.

    OpenUrlPubMed
44. 44.↵
    2. Gilmour LM,
    3. Macleod KG,
    4. McCaig A,
    5. Gullick WJ,
    6. Smyth JF,
    7. Langdon SP.

    Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer. Cancer Res. 2001; 61: 2169–76.

    OpenUrlAbstract/FREE Full Text
45. 45.↵
    2. McAlpine JN,
    3. Wiegand KC,
    4. Vang R,
    5. Ronnett BM,
    6. Adamiak A,
    7. Kobel M, et al.

    HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer. 2009; 9: 433.

    OpenUrlCrossRefPubMed
46. 46.↵
    2. Chao WR,
    3. Lee MY,
    4. Lin WL,
    5. Chen CK,
    6. Lin JC,
    7. Koo CL, et al.

    HER2 amplification and overexpression are significantly correlated in mucinous epithelial ovarian cancer. Hum Pathol. 2014; 45: 810–16.

    OpenUrl
47. 47.↵
    2. Hudis CA.

    Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med. 2007; 357: 39–51.

    OpenUrlCrossRefPubMedWeb of Science
48. 48.↵
    2. Badache A,
    3. Hynes NE.

    A new therapeutic antibody masks ErbB2 to its partners. Cancer Cell. 2004; 5: 299–301.

    OpenUrlCrossRefPubMedWeb of Science
49. 49.↵
    2. Baselga J,
    3. Norton L,
    4. Albanell J,
    5. Kim YM,
    6. Mendelsohn J.

    Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998; 58: 2825–31.

    OpenUrlAbstract/FREE Full Text
50. 50.
    2. Vogel CL,
    3. Cobleigh MA,
    4. Tripathy D,
    5. Gutheil JC,
    6. Harris LN,
    7. Fehrenbacher L, et al.

    Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20: 719–26.

    OpenUrlAbstract/FREE Full Text
51. 51.↵
    2. Buzdar AU,
    3. Ibrahim NK,
    4. Francis D,
    5. Booser DJ,
    6. Thomas ES,
    7. Theriault RL, et al.

    Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2–positive operable breast cancer. J Clin Oncol. 2005; 23: 3676–85.

    OpenUrlAbstract/FREE Full Text
52. 52.↵
    2. McGahan L.

    Herceptin®: monoclonal antibody therapy for metastatic breast cancer. Issues Emerg Health Technol. 1998:1–4.
53. 53.↵
    2. Bookman MA,
    3. Darcy KM,
    4. Clarke-Pearson D,
    5. Boothby RA,
    6. Horowitz IR.

    Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology Group. J Clin Oncol. 2003; 21: 283–90.

    OpenUrlAbstract/FREE Full Text
54. 54.↵
    2. Agus DB,
    3. Akita RW,
    4. Fox WD,
    5. Lewis GD,
    6. Higgins B,
    7. Pisacane PI, et al.

    Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002; 2: 127–37.

    OpenUrlCrossRefPubMedWeb of Science
55. 55.↵
    2. DiGiulio S.

    FDA Approves Perjeta (Pertuzumab) for Neoadjuvant Breast Cancer. Oncol Times. 2013;
56. 56.↵
    2. Baselga J,
    3. Cortes J,
    4. Kim SB,
    5. Im SA,
    6. Hegg R,
    7. Im YH, et al.

    Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012; 366: 109–19.

    OpenUrlCrossRefPubMedWeb of Science
57. 57.↵
    2. Makhija S,
    3. Amler LC,
    4. Glenn D,
    5. Ueland FR,
    6. Gold MA,
    7. Dizon DS, et al.

    Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol. 2010; 28: 1215–23.

    OpenUrlAbstract/FREE Full Text
58. 58.↵
    2. Kurzeder C,
    3. Bover I,
    4. Marme F,
    5. Rau J,
    6. Pautier P,
    7. Colombo N, et al.

    Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE). J Clin Oncol. 2016; 34: 2516–25.

    OpenUrlAbstract/FREE Full Text
59. 59.↵
    2. Sims A,
    3. Zweemer AJ,
    4. Nagumo Y,
    5. Faratian D,
    6. Muir M,
    7. Dodds M, et al.

    Defining the olecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer. Br J Cancer. 2012; 106: 1779–89.

    OpenUrlPubMed
60. 60.↵
    2. Faratian D,
    3. Zweemer AJ,
    4. Nagumo Y,
    5. Sims AH,
    6. Muir M,
    7. Dodds M, et al.

    Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies. Clin Cancer Res. 2011; 17: 4451–61.

    OpenUrlAbstract/FREE Full Text
61. 61.↵
    2. Barok M,
    3. Joensuu H,
    4. Isola J.

    Trastuzumab emtansine: mechanisms of action and drug resistance. Br J Cancer. 2014; 16: 209.

    OpenUrl
62. 62.↵
    2. Verma S,
    3. Miles D,
    4. Gianni L,
    5. Krop IE,
    6. Welslau M,
    7. Baselga J, et al.

    Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med. 2012; 367: 1783–91.

    OpenUrlCrossRefPubMedWeb of Science
63. 63.↵
    2. Guerin M,
    3. Sabatier R,
    4. Goncalves A.

    Trastuzumab emtansine (Kadcyla®) approval in HER2-positive metastatic breast cancers. Bull Cancer. 2015; 102: 390–7.

    OpenUrl
64. 64.↵
    2. Menderes G,
    3. Bonazzoli E,
    4. Bellone S,
    5. Altwerger G,
    6. Black JD,
    7. Dugan K, et al.

    Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. Gynecol Oncol. 2017; 147: 145–52.

    OpenUrl
65. 65.
    2. Nicoletti R,
    3. Lopez S,
    4. Bellone S,
    5. Cocco E,
    6. Schwab CL,
    7. Black JD, et al.

    T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. Clin Exp Metastasis. 2015; 32: 29–38.

    OpenUrl
66. 66.↵
    2. Montero JC,
    3. Garcia-Alonso S,
    4. Ocana A,
    5. Pandiella A.

    Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling. Oncotarget. 2015; 6: 30057–71.

    OpenUrl
67. 67.↵
    2. Yu L,
    3. Wang Y,
    4. Yao Y,
    5. Li W,
    6. Lai Q,
    7. Li J, et al.

    Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model. Int J Gynecol Cancer. 2014; 24: 1158–64.

    OpenUrlAbstract/FREE Full Text
68. 68.↵
    2. Arora A,
    3. Scholar EM.

    Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005; 315: 971–79.

    OpenUrlAbstract/FREE Full Text
69. 69.↵
    2. Gupta S,
    3. El-Rayes BF.

    Small molecule tyrosine kinase inhibitors in pancreatic cancer. Biologics. 2008; 2: 707–15.

    OpenUrlPubMed
70. 70.↵
    2. Roskoski R.

    Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacol Res. 2016; 103: 26–48.

    OpenUrlCrossRefPubMed
71. 71.
    2. Yan M,
    3. Parker BA,
    4. Schwab R,
    5. Kurzrock R.

    HER2 aberrations in cancer: Implications for therapy. Cancer Treat Rev. 2014; 40: 770–80.

    OpenUrlCrossRefPubMedWeb of Science
72. 72.
    2. Wind S,
    3. Schmid M,
    4. Erhardt J,
    5. Goeldner R-G,
    6. Stopfer P.

    Pharmacokinetics of Afatinib, a Selective Irreversible ErbB Family Blocker, in Patients with Advanced Solid Tumours. Clin Pharmacokinet. 2013; 52: 1101–09.

    OpenUrlCrossRefPubMed
73. 73.
    2. Metro G,
    3. Crino L.

    The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer. Expert Rev Anticancer Ther. 2011; 11: 673–82.

    OpenUrlCrossRefPubMed
74. 74.
    2. Van Vuurden D,
    3. Shukla S,
    4. Wedekind L,
    5. Kuipers G,
    6. Noske D.

    Cytotoxicity and Radiosensitization of High Grade Glioma Cells by CI-1033, an Irreversible Pan-ErbB Inhibitor. J Cancer Sci Ther. 2013; 5: 249–55.

    OpenUrl
75. 75.
    2. Engelman JA,
    3. Zejnullahu K,
    4. Gale CM,
    5. Lifshits E,
    6. Gonzales AJ,
    7. Shimamura T, et al.

    PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib. Cancer Res. 2007; 67: 11924–32.

    OpenUrlAbstract/FREE Full Text
76. 76.
    2. Nelson MH,
    3. Dolder CR.

    Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother. 2006; 40: 261–69.

    OpenUrlCrossRefPubMed
77. 77.
    2. Canfield K,
    3. Li J,
    4. Wilkins OM,
    5. Morrison MM,
    6. Ung M,
    7. Wells W, et al.

    Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells. Cell Cycle. 2015; 14: 648–55.

    OpenUrlCrossRefPubMed
78. 78.↵
    2. Hickinson DM,
    3. Klinowska T,
    4. Speake G,
    5. Vincent J,
    6. Trigwell C,
    7. Anderton J, et al.

    AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clin Cancer Res. 2010; 16: 1159–69.

    OpenUrlAbstract/FREE Full Text
79. 79.↵
    2. Burstein HJ,
    3. Sun Y,
    4. Dirix LY,
    5. Jiang Z,
    6. Paridaens R,
    7. Tan AR, et al.

    Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer. J Clin Oncol. 2010; 28: 1301–7.

    OpenUrlAbstract/FREE Full Text
80. 80.
    2. Rabindran SK,
    3. Discafani CM,
    4. Rosfjord EC,
    5. Baxter M,
    6. Floyd MB,
    7. Golas J, et al.

    Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase. Cancer Res. 2004; 64: 3958–65.

    OpenUrlAbstract/FREE Full Text
81. 81.↵
    2. Murphy M,
    3. Stordal B.

    Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review. Drug Resist Updat. 2011; 14: 177–90.

    OpenUrlCrossRefPubMed
82. 82.↵
    2. Schilder RJ,
    3. Sill MW,
    4. Chen X,
    5. Darcy KM,
    6. Decesare SL,
    7. Lewandowski G, et al.

    Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res. 2005; 11: 5539–48.

    OpenUrlAbstract/FREE Full Text
83. 83.↵
    2. Wagner U,
    3. du Bois A,
    4. Pfisterer J,
    5. Huober J,
    6. Loibl S,
    7. Luck HJ, et al.

    Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol Oncol. 2007; 105: 132–37.

    OpenUrlCrossRefPubMedWeb of Science
84. 84.↵
    2. Ohta T,
    3. Ohmichi M,
    4. Shibuya T,
    5. Takahashi T,
    6. Tsutsumi S,
    7. Takahashi K, et al.

    Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells. Cancer Biol Ther. 2012; 13: 408–16.

    OpenUrlPubMed
85. 85.↵
    2. Zhou C,
    3. Wu YL,
    4. Chen G,
    5. Feng J,
    6. Liu XQ,
    7. Wang C, et al.

    Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase III study. Lancet Oncol. 2011; 12: 735–42.

    OpenUrlCrossRefPubMedWeb of Science
86. 86.↵
    2. Sui H,
    3. Shi C,
    4. Yan Z,
    5. Li H.

    Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy. Drug Des Devel Ther. 2015; 9: 3183–90.

    OpenUrlPubMed
87. 87.↵
    2. Hirte H,
    3. Oza A,
    4. Swenerton K,
    5. Ellard SL,
    6. Grimshaw R,
    7. Fisher B, et al.

    A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149). Gynecol Oncol. 2010; 118: 308–12.

    OpenUrlCrossRefPubMed
88. 88.↵
    2. Blank SV,
    3. Christos P,
    4. Curtin JP,
    5. Goldman N,
    6. Runowicz CD,
    7. Sparano JA, et al.

    Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. Gynecol Oncol. 2010; 119: 451–56.

    OpenUrlCrossRefPubMed
89. 89.↵
    2. Warner E,
    3. Liebes L,
    4. Levinson B,
    5. Downey A,
    6. Tiersten A,
    7. Muggia F.

    Continuous-infusion topotecan and erlotinib: a study in topotecan-pretreated ovarian cancer assessing shed collagen epitopes as a marker of invasiveness. Oncologist. 2014; 19: 250.

    OpenUrlAbstract/FREE Full Text
90. 90.↵
    2. Chambers SK,
    3. Clouser MC,
    4. Baker AF,
    5. Roe DJ,
    6. Cui H,
    7. Brewer MA, et al.

    Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res. 2010; 16: 5320–8.

    OpenUrlAbstract/FREE Full Text
91. 91.↵
    2. Vergote IB,
    3. Jimeno A,
    4. Joly F,
    5. Katsaros D,
    6. Coens C,
    7. Despierre E, et al.

    Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study. J Clin Oncol. 2014; 32: 320–26.

    OpenUrlAbstract/FREE Full Text
92. 92.↵
    2. Despierre E,
    3. Vergote I,
    4. Anderson R,
    5. Coens C,
    6. Katsaros D,
    7. Hirsch FR, et al.

    Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy. Target Oncol. 2015; 10: 583–96.

    OpenUrl
93. 93.↵
    2. Burstein HJ,
    3. Storniolo AM,
    4. Franco S,
    5. Forster J,
    6. Stein S,
    7. Rubin S, et al.

    A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol. 2008; 19: 1068–74.

    OpenUrlCrossRefPubMedWeb of Science
94. 94.↵
    2. Kimball KJ,
    3. Numnum TM,
    4. Kirby TO,
    5. Zamboni WC,
    6. Estes JM,
    7. Barnes MN, et al.

    A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma. Gynecol Oncol. 2008; 111: 95–101.

    OpenUrlCrossRefPubMed
95. 95.↵
    2. Lheureux S,
    3. Krieger S,
    4. Weber B,
    5. Pautier P,
    6. Fabbro M,
    7. Selle F, et al.

    Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase II trial. Int J Gynecol Cancer. 2012; 22: 1483–8.

    OpenUrlAbstract/FREE Full Text
96. 96.↵
    2. Weroha SJ,
    3. Oberg AL,
    4. Ziegler KL,
    5. Dakhilm SR,
    6. Rowland KM,
    7. Hartmann LC, et al.

    Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecol Oncol. 2011; 122: 116–20.

    OpenUrlCrossRefPubMed
97. 97.↵
    2. Garcia AA,
    3. Sill MW,
    4. Lankes HA,
    5. Godwin AK,
    6. Mannel RS,
    7. Armstrong DK, et al.

    A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study. Gynecol Oncol. 2012; 124: 569–74.

    OpenUrlCrossRefPubMed
98. 98.↵
    2. Mu Z,
    3. Klinowska T,
    4. Dong X,
    5. Foster E,
    6. Womack C,
    7. Fernandez SV, et al.

    AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models. J Exp Clin Cancer Res. 2014; 33: 47.

    OpenUrl
99. 99.↵
    2. Tjulandin S,
    3. Moiseyenko V,
    4. Semiglazov V,
    5. Manikhas G,
    6. Learoyd M,
    7. Saunders A, et al.

    Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors. Invest New Drugs. 2014; 32: 145–53.

    OpenUrlCrossRefPubMed
100. 100.↵
     2. Solca F,
     3. Dahl G,
     4. Zoephel A,
     5. Bader G,
     6. Sanderson M,
     7. Klein C, et al.

     Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker. J Pharmacol Exp Ther. 2012; 343: 342–50.

     OpenUrlAbstract/FREE Full Text
101. 101.↵
     2. Lewis N,
     3. Marshall J,
     4. Amelsberg A,
     5. Cohen RB,
     6. Stopfer P,
     7. Hwang J, et al.

     A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors. Br J Cancer. 2006; 24: 3091–91.

     OpenUrl
102. 102.↵
     2. Gordon MS,
     3. Mendelson DS,
     4. Gross M,
     5. Uttenreuther-Fischer M,
     6. Ould-Kaci M,
     7. Zhao Y, et al.

     A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Invest New Drugs. 2013; 31: 409–16.

     OpenUrlCrossRefPubMed
103. 103.↵
     2. Ring A,
     3. Wheatley D,
     4. Hatcher H,
     5. Laing R,
     6. Plummer R,
     7. Uttenreuther-Fischer M, et al.

     Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer. Clin Cancer Res. 2015; 21: 2737–44.

     OpenUrlAbstract/FREE Full Text
104. 104.↵
     2. Lin NU,
     3. Winer EP,
     4. Wheatley D,
     5. Carey LA,
     6. Houston S,
     7. Mendelson D, et al.

     A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat. 2012; 133: 1057–65.

     OpenUrlCrossRefPubMedWeb of Science
105. 105.↵
     2. Wang Sq,
     3. Liu St,
     4. Zhao Bx,
     5. Yang Fh,
     6. Wang Yt,
     7. Liang Qy, et al.

     Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1. Oncotarget. 2015; 6: 26142–60.

     OpenUrl
106. 106.↵
     2. Hanker AB,
     3. Brewer MR,
     4. Sheehan JH,
     5. Koch JP,
     6. Sliwoski GR,
     7. Nagy R, et al.

     An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. Cancer Discov. 2017; 7: 575–85.

     OpenUrlAbstract/FREE Full Text
107. 107.↵
     2. Solca F,
     3. Baum A,
     4. Himmelsbach F,
     5. Amelsberg A,
     6. Adolf G.

     Efficacy of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in combination with cytotoxic agents. EJC Suppl. 2006; 4: 172.

     OpenUrl
108. 108.↵
     2. Puvanenthiran S,
     3. Essapen S,
     4. Seddon AM,
     5. Modjtahedi H.

     Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs. Int J Oncol. 2016; 49: 1825–38.

     OpenUrl
109. 109.↵
     2. Carmi C,
     3. Mor M,
     4. Petronini PG,
     5. Alfieri RR.

     Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. Biochem Pharmacol. 2012; 84: 1388–99.

     OpenUrlCrossRefPubMed
110. 110.↵
     2. Slichenmyer WJ,
     3. Elliott WL,
     4. Fry DW.

     CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin Oncol. 2001; 28: 80–85.

     OpenUrlCrossRefPubMedWeb of Science
111. 111.↵
     2. Hassan W,
     3. Chitcholtan K,
     4. Sykes P,
     5. Garrill A.

     A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models. Oncol Ther. 2016; 4: 257–74.

     OpenUrl
112. 112.↵
     2. Campos S,
     3. Hamid O,
     4. Seiden MV,
     5. Oza A,
     6. Plante M,
     7. Potkul RK, et al.

     Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol. 2005; 23: 5597–604.

     OpenUrlAbstract/FREE Full Text
113. 113.↵
     2. Prasasya RD,
     3. Vang KZ,
     4. Kreeger PK.

     A multivariate model of ErbB network composition predicts ovarian cancer cell response to canertinib. Biotechnol Bioeng. 2012; 109: 213–24.

     OpenUrlCrossRefPubMedWeb of Science
114. 114.↵
     2. Deeks ED.

     Neratinib: First Global Approval. Drugs. 2017; 77: 1695–704.

     OpenUrlCrossRef
115. 115.↵
     2. Chan A,
     3. Delaloge S,
     4. Holmes FA,
     5. Moy B,
     6. Iwata H,
     7. Harvey VJ, et al.

     Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet Oncol. 2016; 17: 367–77.

     OpenUrlCrossRefPubMed
116. 116.↵
     2. Sequist LV,
     3. Besse B,
     4. Lynch TJ,
     5. Miller VA,
     6. Wong KK,
     7. Gitlitz B, et al.

     Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010; 28: 3076–83.

     OpenUrlAbstract/FREE Full Text
117. 117.↵
     2. Awada A,
     3. Dirix L,
     4. Manso Sanchez L,
     5. Xu B,
     6. Luu T,
     7. Dieras V, et al.

     Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol. 2013; 24: 109–16.

     OpenUrlCrossRefPubMedWeb of Science
118. 118.
     2. Gandhi L,
     3. Bahleda R,
     4. Tolaney SM,
     5. Kwak EL,
     6. Cleary JM,
     7. Pandya SS, et al.

     Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol. 2014; 32: 68–75.

     OpenUrlAbstract/FREE Full Text
119. 119.
     2. Jankowitz RC,
     3. Abraham J,
     4. Tan AR,
     5. Limentani SA,
     6. Tierno MB,
     7. Adamson LM, et al.

     Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2positive breast cancer: an NSABP Foundation Research Program phase I study. Cancer Chemother Pharmacol. 2013; 72: 1205–12.

     OpenUrlCrossRefPubMed
120. 120.
     2. Saura C,
     3. Garcia-Saenz JA,
     4. Xu B,
     5. Harb W,
     6. Moroose R,
     7. Pluard T, et al.

     Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2014; 32: 3626–33.

     OpenUrlAbstract/FREE Full Text
121. 121.↵
     2. Chow LW,
     3. Xu B,
     4. Gupta S,
     5. Freyman A,
     6. Zhao Y,
     7. Abbas R, et al.

     Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. Br J Cancer. 2013; 108: 1985–93.

     OpenUrlCrossRefPubMed
122. 122.↵
     2. Schwab CL,
     3. English DP,
     4. Black J,
     5. Bellone S,
     6. Lopez S,
     7. Cocco E, et al.

     Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo. Gynecol Oncol. 2015; 139: 112–7.

     OpenUrl
123. 123.↵
     2. Menderes G,
     3. Bonazzoli E,
     4. Bellone S,
     5. Black JD,
     6. Lopez S,
     7. Pettinella F, et al.

     Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo. Med Oncol. 2017; 34: 91.

     OpenUrl
124. 124.↵
     2. Hyman DM,
     3. Piha-Paul SA,
     4. Won H,
     5. Rodon J,
     6. Saura C,
     7. Shapiro GI, et al.

     HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018; 554: 189–94.

     OpenUrlCrossRef
125. 125.↵
     2. Momeny M,
     3. Zarrinrad G,
     4. Moghaddaskho F,
     5. Poursheikhani A,
     6. Sankanian G,
     7. Zaghal A, et al.

     Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells. Sci Rep. 2017; 7: 4204.

     OpenUrlPubMed
126. 126.↵
     2. Calvo E,
     3. Soria JC,
     4. Ma WW,
     5. Wang T,
     6. Bahleda R,
     7. Tolcher AW, et al.

     A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors. Clin Cancer Res. 2017; 23: 1177–85.

     OpenUrlAbstract/FREE Full Text
127. 127.↵
     2. Annunziata CM,
     3. Walker AJ,
     4. Minasian L,
     5. Yu M,
     6. Kotz H,
     7. Wood BJ, et al.

     Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clin Cancer Res. 2010; 16: 664–72.

     OpenUrlAbstract/FREE Full Text
128. 128.↵
     2. Rosen L,
     3. Lopez A,
     4. Mulay M.

     A Phase I/II study of SU101 in patients with ovarian, prostate, and non-small cell lung cancers. Proc Am Soc Clin Oncol; 1997.
129. 129.↵
     2. Chap L,
     3. Chachoua A,
     4. Lopez A,
     5. DePaoli A,
     6. Hannah A.

     A Phase II study of SU101 in patients with advanced ovarian cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol; 1999.
130. 130.↵
     2. Tai CJ,
     3. Lo HY,
     4. Hsu CH,
     5. Tai CJ,
     6. Liu WM.

     Remission of a negative Her2/Neu overexpressive metastatic ovarian cancer patient by the single agent of trastuzumab as salvage therapy. Gynecol Oncol. 2006; 101: 184–5.

     OpenUrlPubMed
131. 131.↵
     2. Paez JG,
     3. Jänne PA,
     4. Lee JC,
     5. Tracy S,
     6. Greulich H,
     7. Gabriel S, et al.

     EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Science. 2004; 304: 1497–500.

     OpenUrlAbstract/FREE Full Text
132. 132.↵
     2. Huang L,
     3. Fu L.

     Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharmaceutica Sinica B. 2015; 5: 390–401.

     OpenUrl
133. 133.↵
     2. Takezawa K,
     3. Pirazzoli V,
     4. Arcila ME,
     5. Nebhan CA,
     6. Song X,
     7. de Stanchina E, et al.

     HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR mutant lung cancers that lack the second-site EGFR T790M mutation. Cancer Discov. 2012; 2: 922–33.

     OpenUrlAbstract/FREE Full Text
134. 134.↵
     2. Kobayashi S,
     3. Boggon TJ,
     4. Dayaram T,
     5. Janne PA,
     6. Kocher O,
     7. Meyerson M, et al.

     EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352: 786–92.

     OpenUrlCrossRefPubMedWeb of Science
135. 135.↵
     2. Yamaguchi F,
     3. Fukuchi K,
     4. Yamazaki Y,
     5. Takayasu H,
     6. Tazawa S,
     7. Tateno H, et al.

     Acquired resistance L747S mutation in an epidermal growth factor receptor-tyrosine kinase inhibitor-naïve patient: A report of three cases. Oncol Lett. 2014; 7: 357–60.

     OpenUrlPubMed
136. 136.↵
     2. Zoppoli G,
     3. Moran E,
     4. Soncini D,
     5. Cea M,
     6. Garuti A,
     7. Rocco I, et al.

     Ras-Induced Resistance to Lapatinib is Overcome by MEK Inhibition. Curr Cancer Drug Targets. 2010; 10: 168–75.

     OpenUrlCrossRefPubMed
137. 137.
     2. Kim EJ,
     3. Jeong JH,
     4. Bae S,
     5. Kang S,
     6. Kim CH,
     7. Lim YB.

     mTOR inhibitors radiosensitize PTEN-deficient non-small-cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy. J Cell Biochem. 2013; 114: 1248–56.

     OpenUrl
138. 138.↵
     2. Lovly CM.

     Combating acquired resistance to tyrosine kinase inhibitors in lung cancer. Am Soc Clin Oncol Educ Book. Published online first: May 31, 2015. DOI: 10.14694/EdBook_AM.2015.35.e165.

     OpenUrlCrossRef
139. 139.↵
     2. Della Corte CM,
     3. Fasano M,
     4. Papaccio F,
     5. Ciardiello F,
     6. Morgillo F.

     Role of HGF–MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer. Biomedicines. 2014; 2: 345–58.

     OpenUrl
140. 140.↵
     2. Chen CT,
     3. Kim H,
     4. Liska D,
     5. Gao S,
     6. Christensen JG,
     7. Weiser MR.

     MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells. Mol Cancer Ther. 2012; 11: 660–69.

     OpenUrlAbstract/FREE Full Text
141. 141.↵
     2. Dohse M,
     3. Scharenberg C,
     4. Shukla S,
     5. Robey RW,
     6. Volkmann T,
     7. Deeken JF, et al.

     Comparison of ATP-Binding Cassette Transporter Interactions with the Tyrosine Kinase Inhibitors Imatinib, Nilotinib, and Dasatinib. Drug Metab Dispos. 2010; 38: 1371–80.

     OpenUrlAbstract/FREE Full Text
142. 142.↵
     2. Fitzgerald JB,
     3. Schoeberl B,
     4. Nielsen UB,
     5. Sorger PK.

     Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol. 2006; 2
143. 143.↵
     2. Booth L,
     3. Roberts JL,
     4. Samuel P,
     5. Avogadri-Connors F,
     6. Cutler RE,
     7. Lalani AS, et al.

     The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells. Cancer Biol Ther. 2018; 19: 525–33.

     OpenUrl
144. 144.↵
     2. Swisher EM,
     3. Sakai W,
     4. Karlan BY,
     5. Wurz K,
     6. Urban N,
     7. Taniguchi T.

     Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum Resistance. Cancer Res. 2008; 68: 2581–86.

     OpenUrlAbstract/FREE Full Text
145. 145.↵
     2. Januchowski R,
     3. Zawierucha P,
     4. Andrzejewska M,
     5. Ruciński M,
     6. Zabel M.

     Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines. Biomed Pharmacother. 2013; 67: 240–45.

     OpenUrlCrossRefPubMed
146. 146.↵
     2. Zhao XQ,
     3. Xie JD,
     4. Chen XG,
     5. Sim HM,
     6. Zhang X,
     7. Liang YJ, et al.

     Neratinib Reverses ATP-Binding Cassette B1-Mediated Chemotherapeutic Drug Resistance In Vitro, In Vivo, and Ex Vivo. Mol Pharmacol. 2012; 82: 47–58.

     OpenUrlAbstract/FREE Full Text
147. 147.
     2. Kathawala RJ,
     3. Gupta P,
     4. Ashby CR Jr.,
     5. Chen ZS.

     The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade. Drug Resist Updat. 2015; 18: 1–17.

     OpenUrlCrossRefPubMed
148. 148.↵
     2. Dai C-l,
     3. Tiwari AK,
     4. Wu C-P,
     5. Su X-d,
     6. Wang S-R,
     7. Liu D-g, et al.

     Lapatinib (Tykerb®, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2. Cancer Res. 2008; 68: 7905–14.

     OpenUrlAbstract/FREE Full Text